Paper - WANFANG MED ONLINE

You Position: Home > Paper

Role of regulatory T cells in pathogenesis and therapy of autoimmune liver disease

( views:23, downloads:0 )

Author:: No author available

Journal Title:: World Chinese Journal of Digestology

Issue:: 11

DOI:: 10.11569/wcjd.v27.i11.665

Key Word:: 自身免疫性肝病;调节性T田胞;发病机制;免疫治疗

Abstract：自身免疫性肝病(autoimmune liver disease,AILD)是一组由自身免疫介导的肝胆损伤,其包括自身免疫性肝炎,原发性胆汁性胆管炎和原发性硬化性胆管炎.多项研究表明基因易感性、分子模拟、异常的免疫调节网络对AILD的发生与发展具有促进作用,但其自身免疫环境异常的原因至今尚未明确.目前认为,自身免疫性疾病的发生主要由自身免疫耐受机制破坏所致.调节性T细胞(regulatoryT cells,Treg)是外周免疫耐受的关键,故可能在AILD中发挥重要的作用.本文从Treg细胞角度阐述AILD的发病机制,并对Treg细胞在AILD治疗中的应用作一阐述.

Reference

[1]Ping, Wang,Song Guo, Zheng.Regulatory T cells and B cells: implication on autoimmune diseases.[J].2013,6(12).
[2]Ruth Y. Lan,Chunmei Cheng,Zhe-Xiong Lian,etc.Liver-targeted and peripheral blood alterations of regulatory T cells in primary biliary cirrhosis[J].2006,43(4).
[3]Granito A,Ma Y,Longhi MS,etc.A multifaceted imbalance of T cells with regulatory function characterizes type 1 autoimmune hepatitis.[J].2010,52(3).
[4]Yimam,K.K.,Bowlus,C.L..Diagnosis and classification of primary sclerosing cholangitis[J].2014,13(4).
[5]Beth S. Holder,Charlotte R. Grant,Rodrigo Liberal,etc.Retinoic acid stabilizes antigen-specific regulatory T-cell function in autoimmune hepatitis type 2[J].2014,53.
[6]Amir,Sharabi,Maria G,Tsokos,Ying,Ding,etc.Regulatory T cells in the treatment of disease.[J].2018.
[7]Maria Serena Longhi,Yun Ma,Ragai R. Mitry,etc.Effect of CD4+CD25+ regulatory T-cells on CD8 T-cell function in patients with autoimmune hepatitis[J].2005,25(1).
[8]H Tanaka.Successful immunotherapy of autoimmune cholangitis by adoptive transfer of forkhead box protein 3+ regulatory T cells[J].2014,178(2).
[9]He, Jing,Zhang, Xia,Wei, Yunbo,etc.Low-dose interleukin-2 treatment selectively modulates CD4(+) T cell subsets in patients with systemic lupus erythematosus[J].2016,22(9).
[10]Evaggelia Liaskou,Samita R. Patel,Gwilym Webb,etc.Increased sensitivity of Treg cells from patients with PBC to low dose IL-12 drives their differentiation into IFN-γ secreting cells[J].2018,94.
[11]Rodriguez E. A.,Carey E. J.,Buness C. W.,etc.Review article: the evidence that vancomycin is a therapeutic option for primary sclerosing cholangitis[J].2018,47(7).
[12]Oo YH,Weston CJ,Lalor P.Distinct roles for CCR4 and CXCR3 in the recruitment and positioning of regulatory T cells in the inflamed human liver.[J].2010,184(6).
[13]Bowlus,C.L.,Gershwin,M.E..The diagnosis of primary biliary cirrhosis[J].2014,13(4).
[14]Ma,Y.,Holder,B.S.,Longhi,M.S.,etc.The impaired immune regulation of autoimmune hepatitis is linked to a defective galectin-9/tim-3 pathway[J].2012,56(2).
[15]Grant,C.R.,Liberal,R.,Holder,B.S.,etc.Dysfunctional CD39POS regulatory T cells and aberrant control of T-helper type 17 cells in autoimmune hepatitis[J].2014,59(3).
[16]S, Vento,J E, Hegarty,G, Bottazzo,etc.Antigen specific suppressor cell function in autoimmune chronic active hepatitis.[J].1984,1(8388).
[17]Liberal,R.,Mieli-Vergani,G.,Vergani,D..Clinical significance of autoantibodies in autoimmune hepatitis[J].2013,46.
[18]Antonio La Cava.Tregs in SLE: an Update[J].2018,20(2).
[19]Strassburg,C.P.,Manns,M.P..Therapy of autoimmune hepatitis[J].2011,25(6).
[20]Bynoe MS,Viret C.Foxp3(+)CD4(+) T cell-mediated immunosuppression involves extracellular nucleotide catabolism.[J].2008,29(3).
[21]Das Madhumita,Zhu Chen,Kuchroo Vijay K..Tim-3 and its role in regulating anti-tumor immunity[J].2017,276(1).
[22]Card TR,Solaymani-Dodaran M,West J.Incidence and mortality of primary sclerosing cholangitis in the UK: A population-based cohort study.[J].2008,48(6).
[23]Karlsen,T.H.,Schrumpf,E.,Boberg,K.M..Update on primary sclerosing cholangitis[J].2010,42(6).
[24]Petersen, Britt-Sabina,Schoknecht, Tanja,Olek, Sven,etc.Reduced FOXP3(+) regulatory T cells in patients with primary sclerosing cholangitis are associated with IL2RA gene polymorphisms[J].2014,60(5).
[25]Blachier,M.,Leleu,H.,Peck-Radosavljevic,M.,etc.The burden of liver disease in Europe: A review of available epidemiological data[J].2013,58(3).
[26]Eaton,J.E.,Talwalkar,J.A.,Lazaridis,K.N.,etc.Pathogenesis of primary sclerosing cholangitis and advances in diagnosis and management[J].2013,145(3).
[27]Oo YH,Hubscher SG,Adams DH.Autoimmune hepatitis: new paradigms in the pathogenesis, diagnosis, and management.[J].2010,4(2).
[28]Klatzmann, David,Abbas, Abul K..The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases[J].2015,15(5).
[29]Jorgensen,R.A.,Keach,J.C.,Talwalkar,J.A.,etc.Randomised clinical trial: Vancomycin or metronidazole in patients with primary sclerosing cholangitis - A pilot study[J].2013,37(6).
[30]Vergani,D.,Longhi,M.S.,Holder,B.,etc.Inhibition of interleukin-17 promotes differentiation of CD25 - cells into stable T regulatory cells in patients with autoimmune hepatitis[J].2012,142(7).
[31]Schwinge, Dorothee,von Haxthausen, Franziska,Quaas, Alexander,etc.Dysfunction of hepatic regulatory T cells in experimental sclerosing cholangitis is related to IL-12 signaling[J].2017,66(4).
[32]Vento S.,O'Brien C.J.,McFarlane Barbara M.,etc.T-lymphocyte sensitization to hepatocyte antigens in autoimmune chronic active hepatitis and primary biliary cirrhosis[J].1986.
[33]Carlo, Selmi,Natalie J, Torok,Andrea, Affronti,etc.Genomic variants associated with primary biliary cirrhosis.[J].2010,2(1).
[34]Romano Marco,Tung Sim Lai,Smyth Lesley Ann,etc.Treg therapy in transplantation: a general overview[J].2017,30(8).
[35]Rodrigo, Liberal,Charlotte R, Grant,Maria Serena, Longhi,etc.Diagnostic criteria of autoimmune hepatitis.[J].1900,13(4-5).
[36]Charles J,Malemud.Defective T-Cell Apoptosis and T-Regulatory Cell Dysfunction in Rheumatoid Arthritis.[J].2018,7(12).
[37]Davies YK,Cox KM,Abdullah BA,etc.Long-term treatment of primary sclerosing cholangitis in children with oral vancomycin: an immunomodulating antibiotic.[J].2008,47(1).
[38]Lapierre,P.,Alvarez,F.,Béland,K.,etc.Adoptive transfer of ex vivo expanded regulatory T cells in an autoimmune hepatitis murine model restores peripheral tolerance[J].2013,57(1).
[39]Mantovani, Stefania,Mondelli, Mario U.,Maggiore, Giuseppe,etc.Altered natural killer cell cytokine profile in type 2 autoimmune hepatitis[J].2018,188.
[40]Lindor KD,Poupon R,Gershwin ME.Primary biliary cirrhosis.[J].2009,50(1).
[41]Vergani D,Hussain MJ,Longhi MS,etc.Functional study of CD4+CD25+ regulatory T cells in health and autoimmune hepatitis.[J].2006,176(7).